Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31605956 | 1.00 | BACE1 (0.40) | BACE1DYRK1AROCK1MAP2K1CHEK1 | |
| SCHEMBL16243780 | 0.76 | BACE1 (0.42) | BACE1DYRK1AMAPTKDM4EALDH1A1 | |
| SCHEMBL30739111 | 0.75 | MAPT (0.40) | BACE1MAP2K1MAPTKDM4EALDH1A1 | |
| SCHEMBL31731911 | 0.73 | MAPK8 (0.42) | KDM4EALDH1A1HSD17B10MAPK8 | |
| SCHEMBL8518248 | 0.72 | TNKS2 (0.40) | MAPTKDM4EHPGDHSD17B10 | |
| SCHEMBL29909014 | 0.72 | TNKS2 (0.40) | MAPTKDM4EHPGDHSD17B10 | |
| SCHEMBL11536510 | 0.71 | ROCK1 (0.46) | DYRK1AROCK1MAP2K1CHEK1MAP4K4 | |
| SCHEMBL1104796 | 0.71 | ROCK1 (0.46) | DYRK1AROCK1MAP2K1CHEK1MAP4K4 | |
| SCHEMBL29881244 | 0.71 | NPSR1 (0.47) | DYRK1AMAPTKDM4EALDH1A1GLA | |
| SCHEMBL12638627 | 0.69 | PARP1 (0.39) | MAP2K1MAPTKDM4EALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435092-B2 | Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG | 858 THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240352018-A1 | SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2024-10-24 | — | — | US | disclosed |
| US-11939335-B2 | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG | 858 THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11939335-B2 | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG | 858 THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230374022-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-9598433-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9580463-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150376233-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-31 | — | — | US | disclosed |
| US-20150284409-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-10-08 | — | — | US | disclosed |
| US-8803134-B2 | Biscarbazole derivatives and organic electroluminescence | IDEMITSU KOSAN CO., LTD. (JP) | 2014-08-12 | — | — | US | disclosed |
| US-20120223295-A1 | BISCARBAZOLE DERIVATIVES AND ORGANIC ELECTROLUMINESCENCE | IDEMITSU KOSAN CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7919621-B2 | Tricyclic inhibitors of 5-lipoxygenase | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | AMIRA PHARMACEUTICALS, INC. (US) | 2007-07-26 | — | — | US | disclosed |
| US-20060040934-A1 | Use of STAT-6 inhibitors as therapeutic agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2006-02-23 | — | — | US | disclosed |
| US-20030232794-A1 | Use of STAT-6 inhibitors as therapeutic agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-18 | — | — | US | disclosed |
| US-20030143199-A1 | Use of STAT-6 inhibitors as therapeutic agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-31 | — | — | US | disclosed |
| WO-2002014321-A9 | USE OF STAT-6 INHIBITORS AS THERAPEUTIC AGENTS | UNIV CALIFORNIA (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002014321-A1 | USE OF STAT-6 INHIBITORS AS THERAPEUTIC AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374022-A1 | INHIBITORS OF PARG | PARG, PLG, SERPINB1 | BACE1 1218/4885DYRK1A 3640/4885ROCK1 902/4885 |
| US-12435092-B2 | Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG | PARG, PLG, PTGIS | BACE1 2049/4885DYRK1A 2962/4885ROCK1 1230/4885 |
| US-20070173508-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | BACE1 2373/4885DYRK1A 4663/4885ROCK1 2726/4885 |
| US-20150284409-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, GOT1 | BACE1 4150/4885DYRK1A 4879/4885ROCK1 3609/4885 |
| US-20030143199-A1 | Use of STAT-6 inhibitors as therapeutic agents | STAT4, STAT3, STAT1 | BACE1 4696/4885DYRK1A 1478/4885ROCK1 476/4885 |
| US-20110112106-A1 | TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE | ALOX5, ALOX15, ALOX15B | BACE1 2373/4885DYRK1A 4663/4885ROCK1 2726/4885 |
| US-20060040934-A1 | Use of STAT-6 inhibitors as therapeutic agents | STAT3, STAT1, STAT4 | BACE1 4815/4885DYRK1A 199/4885ROCK1 546/4885 |
| US-20120223295-A1 | BISCARBAZOLE DERIVATIVES AND ORGANIC ELECTROLUMINESCENCE | EED, GABRE, EML4 | BACE1 1978/4885DYRK1A 1628/4885ROCK1 4292/4885 |
| US-20150376233-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, HCCS, GOT1 | BACE1 4150/4885DYRK1A 4879/4885ROCK1 3609/4885 |
| US-20030232794-A1 | Use of STAT-6 inhibitors as therapeutic agents | STAT3, STAT1, STAT4 | BACE1 4815/4885DYRK1A 199/4885ROCK1 546/4885 |
| US-20240352018-A1 | SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG | PARG, PLG, PARN | BACE1 2288/4885DYRK1A 2119/4885ROCK1 2125/4885 |
| US-11939335-B2 | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG | PARG, PTGIS, PLG | BACE1 2115/4885DYRK1A 2533/4885ROCK1 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.